The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy

Frontiers in Immunology

Immunology

Ruonan Li¹  Lili Cao² 

[1] Oncology Department, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China;Oncology Department, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China;Shandong Provincial Key Laboratory for Rheumatic Disease and Translational Medicine and Shandong Lung Cancer Institute, Jinan, China;

关键词: triple-negative breast cancer (TNBC);    tumor-infiltrating lymphocytes (TILs);    adoptive cell therapy (ACT);    breast cancer;    solid tumor;   

DOI  :  10.3389/fimmu.2023.1194020

 received in 2023-03-26, accepted in 2023-05-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

The treatment outcome of breast cancer is closely related to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Triple-negative breast cancer (TNBC) lacking ER, PR, and HER2 expression has limited treatment options and a poor prognosis. Tumor-infiltrating lymphocytes (TILs) play a role in promoting or resisting tumors by affecting the tumor microenvironment and are known as key regulators in breast cancer progression. However, treatments for TNBC (e.g., surgery, chemotherapy and radiotherapy) have non-satisfaction’s curative effect so far. This article reviews the role of different types of TILs in TNBC and the research progress of adoptive cell therapy, aiming to provide new therapeutic approaches for TNBC.

【 授权许可】

Unknown   
Copyright © 2023 Li and Cao